Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.68 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1495367 | 0.85 | P2RX3 (0.65) | P2RX3P2RX2HDAC4HDAC6L3MBTL1 | |
| SCHEMBL13014788 | 0.84 | P2RX3 (0.61) | P2RX3P2RX2HDAC4HDAC6 | |
| SCHEMBL10187943 | 0.84 | P2RX3 (0.73) | P2RX3P2RX2HDAC4HDAC6L3MBTL1 | |
| SCHEMBL405831 | 0.84 | P2RX3 (0.73) | P2RX3P2RX2HDAC4HDAC6L3MBTL1 | |
| SCHEMBL406256 | 0.82 | P2RX3 (0.73) | P2RX3P2RX2HDAC4HDAC6L3MBTL1 | |
| SCHEMBL12757547 | 0.82 | P2RX3 (0.61) | P2RX3P2RX2HDAC4HDAC6L3MBTL1 | |
| SCHEMBL13774506 | 0.82 | P2RX3 (0.66) | P2RX3P2RX2HDAC4HDAC6L3MBTL1 | |
| SCHEMBL406888 | 0.82 | P2RX3 (0.73) | P2RX3P2RX2HDAC4HDAC6L3MBTL1 | |
| SCHEMBL10225823 | 0.81 | P2RX3 (0.62) | P2RX3P2RX2HDAC4HDAC6L3MBTL1 | |
| SCHEMBL10243057 | 0.81 | P2RX3 (0.62) | P2RX3P2RX2HDAC4HDAC6L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083500-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X 2/3 ANTAGONISTS | CHEN LI (CN) | 2012-04-05 | — | — | US | disclosed |
| US-8119644-B2 | Thiadiazole-substituted arylamides as P2X3 and P2X2/3 antagonists | Roche Palo Alto LLP (US) | 2012-02-21 | — | — | US | disclosed |
| US-8093275-B2 | Oxazolone and pyrrolidinone-substituted pryidine amides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2379518-A1 | THIADIAZOLE-SUBSTITUTED ARYLAMIDES | F. Hoffmann-La Roche AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-20110245271-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC. | 2011-10-06 | — | — | US | disclosed |
| US-7989637-B2 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2011-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083500-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X 2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX1 | P2RX3 1/4885P2RX2 2/4885HDAC4 3407/4885 |
| US-20110245271-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | P2RX3 1/4885P2RX2 2/4885HDAC4 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.